Johnson & Johnson’s second quarter sales rose, but its orthopedic segment sales saw a less than 1% decrease, according to financial results posted July 16.
Five things to know:
1. Global orthopedic sales of $2.3 billion, falling 0.3% short compared to the same period in 2024.
2. Hip sales of $421 million represent a 1% increase year over year, and knee sales of $389 million is a 1.1% decrease.
3. Spine, sports and other sales decreased 2.1% year over year with $727 million. Trauma sales increased 1.2% in the second quarter with $768 million.
4. The dip in orthopedic sales was due to “competitive pressures, the transformation program, and China volume-based procurement,” Johnson & Johnson CFO Darren Snellgrove, said in a quarterly earnings call.
5. Johnson & Johnson’s total second quarter sales grew 5.8% year over year with $23.7 billion.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
